Musculoskeletal Tumor Center | Scientific and Technological Achievements of Prof. Guo Wei’s Team Realized Transformation
2021-02-12
On February 8, 2021, the signing ceremony for the transformation of scientific and technological achievements of Prof. Guo Wei’s team from the Musculoskeletal Tumor Center, Peking University People's Hospital (PKUPH) was held in Ludaopei Lecture Hall of PKUPH. Leadership from PKUPH and representatives from AK Medical Holding Limited attended the event.
Bone tumors are tumors that occur in the boneits accessory tissues. For a long time, the pelvis has been deemed as a forbidden area for bone tumor surgery. In 2015, Prof. Guo Wei's team developed a full range of 3D printed pelvic ring endoprostheses (Global Pelvic System, GPS), including sacral endoprosthesis, iliac endoprosthesis and acetabular endoprostheses. So far, the GPS endoprostheses have been applied in more than 300 clinical cases and have achieved desirable clinical results with greatly reduced complications.
In 2017, Prof. Guo Wei’s team published an article entitled “Reconstruction with 3D-printed pelvic endoprostheses after resection of a pelvic tumor” in The Bone & Joint Journal (BJJ), which reported the feasibility of using 3D-printing technology for patients with a pelvic tumor who underwent resection of the tumor and reconstruction of the bone defect. Prof. Guo Wei’s team also firstly reported the evidence of osseointegration between 3D-printed porously trabecular interface and the host bone in the world. Through research, it has been found that the use of 3D-printed pelvic prostheses was safe, without additional complications, and gave satisfactory functional results.
The research results of Prof.Guo Wei’s team have successively received the Second Prize of the National Science and Technology Progress Award, the First Prize of China Medical Science and Technology Progress Award, and the Second Prize of Beijing Science and Technology Progress Award. The system now has been internationally recognized as the best therapeutic solution for reconstruction of the pelvic ring following tumor resection.
At the ceremony, Prof. Wang Tianbing, Vice President of PKUPH and Mr. Li Zhijiang, Chairman, Chief Executive Officer and Executive Director of AK Medical Holding Limited signed the agreement on behalf of both parties. Under the agreement, nine patents of Prof. Guo Wei’s team will undergo transformation process.
It is reported that the signing of the technology transformation agreement has realized the goal of China’s independent research and development of endoprostheses for pelvic tumors, which will break the monopoly of imported products, and set a model for the marketization of Chinas original medical technology research and development achievements.
